Abstract: Disclosed is an OPC UA-based centralized user configuration method and system for a time-sensitive network. The system includes user terminal stations, a UA-TSN configuration management middleware and a centralized user configuration entity. The user terminal station includes a plurality of field devices and a UA-TSN coordinator; the UA-TSN configuration management middleware obtains an OPC UA address information list by accessing the UA-TSN coordinator; and the centralized user configuration entity extracts and analyzes TSN stream demand information aggregated in the UA-TSN configuration management middleware. According to the present disclosure, the automatic transmission and configuration of TSN network scheduling information are realized, and the operation complexity in the large-scale TSN network configuration process is reduced.

Abstract: Disclosed is an OPC UA-based centralized user configuration method and system for a time-sensitive network. The system includes user terminal stations, a UA-TSN configuration management middleware and a centralized user configuration entity. The user terminal station includes a plurality of field devices and a UA-TSN coordinator; the UA-TSN configuration management middleware obtains an OPC UA address information list by accessing the UA-TSN coordinator; and the centralized user configuration entity extracts and analyzes TSN stream demand information aggregated in the UA-TSN configuration management middleware. According to the present disclosure, the automatic transmission and configuration of TSN network scheduling information are realized, and the operation complexity in the large-scale TSN network configuration process is reduced.

Abstract: The present invention discloses 3D-structure of SARS-CoV Viral 3CL Protease obtained through molecular simulation. The 3D-structure is used as a drug target for screening the existing medical database CMC (Comprehensive Medicinal Chemistry, MDL Information System, Inc.), and a group of compounds which have the activity of inhibiting SARS-CoV virus 3CL Protease are found. Cinanserin was tested at molecular and viral levels, and it was found to be able to inhibit the SARS-CoV viral 3CL protease and SARS-CoV viruses. Cinanserin analogs were synthesized and tested at molecular and viral levels, they were found to be able to inhibit the SARS-CoV virus 3CL Protease and SARS-CoV viruses, and may be used for treating and/or preventing SARS-CoV virus infection.

Abstract: The present invention discloses 3D-structure of SARS-CoV Viral 3CL Protease obtained through molecular simulation. The 3D-structure is used as a drug target for screening the existing medical database CMC (Comprehensive Medicinal Chemistry, MDL Information System, Inc.), and a group of compounds which have the activity of inhibiting SARS-CoV virus 3CL Protease are found. Cinanserin was tested at molecular and viral levels, and it was found to be able to inhibit the SARS-CoV viral 3CL protease and SARS-CoV viruses. Cinanserin analogs were synthesized and tested at molecular and viral levels, they were found to be able to inhibit the SARS-CoV virus 3CL Protease and SARS-CoV viruses, and may be used for treating and/or preventing SARS-CoV virus infection.

Abstract: A method for providing a feature in a telecommunications network is disclosed. Signals representing a call are received at a call agent to generate a detection point. The call is associated with a service identifier corresponding to a set of features. A feature server is identified from a number of feature servers. The identified feature server is notified of the detection point. The signals are processed in response to the detection point to provide a feature from the set of features.